

Dkt. 55873-BA-PCT-US/JPW/AJM/AAB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ann Marie Schmidt, et al.

U.S. Serial No.: 10/665,867

Filed : September 19, 2003

For : Extracellular RAGE Binding Protein (EN-RAGE) and Uses Thereof

1185 Avenue of the Americas
New York, New York 10036
January 6, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant directs the Examiner's attention to the following disclosures, which are listed on Form PTO-1449 (**Exhibit A**).

1. U.S. Patent No. 5,688,653, November 18, 1997 (Ulrich, et al.);
2. U.S. Patent No. 5,864,018, January 26, 1999 (Morser, et al.);
3. U.S. Patent No. 5,976,832, November 2, 1999 (Hitomi, et al.);
4. Morser et al. PCT International Application No. PCT/EP97/01832, filed April 11, 1997, published October

Applicant : Ann Marie Schmidt, et al.

Serial No.: 10/665,687

Filed : September 19, 2003

Page 2

23 1997; Publication No. WO 97/39121, Advanced Glycation Endproduct Receptor Peptides and Uses Thereof;

5. Morser et al. PCT International Application No. PCT/EP97/01834, filed April 11, 1997, published October 23 1997; Publication No. WO 97/39125, Antibodies Against the Advanced Glycation Endproduct Receptor and Uses Thereof;
6. Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412;
7. Borchelt, D. R., et al. (1996). Familial Alzheimer's Disease-linked presenilin 1 variants elevate A β 1-42/1-40 ratio *in vitro* and *in vivo*. Neuron 17: 1005-1013;
8. Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6):1699-1712;
9. Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15(12):1835-1842;
10. Cai, X-D., et al. (1993). Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259: 514-516;
11. Citron, M., et al. (1997). Mutant presenilins of Alzheimer's Disease increase production of 42-residue amyloid β -protein in both transfected cells and transgenic mice. Nature Medicine 3(1): 67-72;

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/665,687
Filed : September 19, 2003
Page 3

12. Dell'Angelica, E.C., et al. (1994). Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J. Biol. Chem. 269: 28929-28936;
13. Fahey, T., et al. (1991). Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res. 50: 308-313;
14. Fu, M-X., et al. (1996). The advanced glycation end product, N^ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986;
15. Giardino, I., et al. (1994). Nonenzymatic glycosylation *in vitro* and in bovine endothelial cells alters basic fibroblast growth factor activity. J. Clin. Invest. 94: 110-117;
16. Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for vascular diseases. Science 272: 689-693;
17. Hofmann, M. A., et al. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell 97:889-901 (**Exhibit 1**);
18. Hori, O., et al. (1995). The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphotericin J. Biol. Chem. 270: 25752-25761;

Applicant : Ann Marie Schmidt, et al.

Serial No.: 10/665,687

Filed : September 19, 2003

Page 4

19. Khoury, J. E., et al., (1994). Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J. Biol. Chem. 269: 10197-10200;
20. Kuo, Y-M., et al. (1996). Water-soluble A β (N-40, N-42) oligomers in normal and Alzheimer Disease brains. J. Biol. Chem. 271(8): 4077-4081;
21. Lander, H. M., et al. (1997). Activation of the receptor for advanced glycation end products triggers a p21^{ras} dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272: 17810-17814;
22. Ledesma, M. D., et al. (1994). Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 269(34):21614-21619;
23. Li, J. and A.M. Schmidt (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272: 16498-16506;
24. Lorenzo, A. and B.A. Yanker (1994). β -amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Nat. Acad. Sci. USA 91: 12243-12247;
25. Mattson, M. P. and Y. Goodman (1995). Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 676: 219-224;

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/665,687
Filed : September 19, 2003
Page 5

26. Miyata, T., et al. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE- β 2 Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J. Clin. Invest. 98: 1088-1094;
27. Nakamura, Y., et al. (1993). Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143(6): 1649-1656;
28. Nepper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267: 14998-15004;
29. Palinski, W., et al. (1995). Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscl. Thromb. and Vasc. Biol. 15(5): 571-582;
30. Park, L., et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4: 1025-1031;
31. Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079;
32. Reddy, S., et al. (1995). N^ε-(Carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878;

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/665,687
Filed : September 19, 2003
Page 6

33. Renard, C., et al. (1997). Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharm. 52: 54-62;
34. Ritthaler, U., et al. (1995). Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease, Am. J. Pathol. 146: 688-694;
35. Roher, A. E., et al. (1996). Morphology and toxicity of A β -(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's Disease. J. Biol. Chem. 271(34): 20631-20635;
36. Schleicher, E. D., et al. (1997). Increased accumulation of the glycoxidation product N $^{\epsilon}$ -(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99: 457-468;
37. Schmidt, A. M., et al. (1995). Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J. Clin. Invest. 96: 1395-1403;
38. Schmidt, A. M., et al. (1994). Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Nat'l Acad. Sci. USA 91: 8807-8811;
39. Schmidt, A. M., et al. (1992). Isolation and characterization of two binding proteins for advanced

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/665,687
Filed : September 19, 2003
Page 7

glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267: 14987-14997;

40. Schmidt, A. M., et al. (1994). Cellular receptors for advanced glycation end products. Arterioscler. Thromb. 14:1521-1528;
41. Schmidt, A. M., et al. (1995). The dark side of glucose. (News and Views). Nature Medicine 1: 1002-1004;
42. Schmidt, A. M., et al. (1993). Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 92: 2155-2168;
43. Schmidt, A. M., et al. (1997). The V-domain of receptor for advanced glycation endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetic complications. Circulation Supplement 96:#194, p. I-37;
44. Schmidt, A. M., et al. (1994). The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J. Biol. Chem. 269: 9882-9888;
45. Schmidt, A.M., et al. (1998). RAGE: a receptor with a taste for multiple ligands and varied pathophysiologic states. Hormones and Signaling 1:41-63;
46. Sell, D., et al. (1989). Structure elucidation of a senescence cross-link from human extracellular matrix;

Applicant : Ann Marie Schmidt, et al.

Serial No.: 10/665,687

Filed : September 19, 2003

Page 8

implication of pentoses in the aging process. J. Biol. Chem. 264:21597-21602;

47. Soulis, T., et al. (1997). Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40: 619-628;
48. Turner, R.S., et al. (1997). Amyloids β_{40} and β_{42} are generated intracellularly in cultured human neurons and their secretion increases with maturation. J. Biol. Chem. 271(15): 8966-8970;
49. Vitek, M.P., et al. (1994). Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Nat'l Acad. Sci. USA 91: 4766-4770;
50. Vlassara, H., et al. (1995). Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Molec. Med. 1: 634-646;
51. Vlassara, H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70: 138-151;
52. Vlassara, H., et al. (1995). Identification of Galectin-3 as a high affinity binding protein for advanced glycation end products. Arterioscler. Thromb. 14:1521-1528;
53. Wautier, J.-L., et al. (1996). Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy:

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/665,687
Filed : September 19, 2003
Page 9

soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97: 238-243;

54. Wautier, J.-L., et al. (1996). Interaction of diabetic erythrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction. Circulation Supplement 94(8): #4139;
55. Wu J., et al. (1997). The soluble receptor for advanced glycation endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. Plastic Surg. Res. Council Abstract #77, p. 43;
56. Yan, S. D., et al. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269: 9889-9897;
57. Yan, S. D., et al. (1996). RAGE and amyloid- β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691;
58. Yan, S. D., et al. (1997). Amyloid- β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Nat'l Acad. Sci. 94: 5296-5301.

The subject application is a continuation of and claims the benefit under 35 U.S.C. §120 of U.S. Serial No. 09/826,589, filed April 5, 2001, which is a continuation of PCT

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/665,687
Filed : September 19, 2003
Page 10

International Application No. PCT/US99/23303, filed October 6, 1999, designating the United States of America, which is a continuation-in-part and claims priority of U.S. Serial No. 09/263,312, filed March 5, 1999, now U.S. Patent No. 6,555,340 B1, issued April 29, 2003, which is a continuation-in-part and claims priority of U.S. Serial No. 09/167,705, filed October 6, 1998, the contents of which are incorporated by reference in their entirety into the present application.

Above-listed references 1, 6-16, 19-33, 35-44, 47-51 and 53-58 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed in connection with U.S. Serial No. 09/167,705, filed October 6, 1998. Above-listed references 2, 18 and 34 were cited by the United States Patent and Trademark Office in an Office Action dated March 24, 1998 in connection with 09/167,705, filed October 6, 1998. Above-listed references 4 and 5 were submitted to and considered by the United States Patent and Trademark Office in a Supplemental Information Disclosure Statement filed on June 18, 2001 in connection with U.S. Serial No. 09/167,705, filed October 6, 1998. Above-listed reference 3 was cited by the United States Patent and Trademark Office in an Office Action dated December 19, 2000 in connection with 09/263,312, filed March 5, 1999, now U.S. Patent No. 6,555,340 B1, issued April 29, 2003. Above-listed references 45, 46 and 52 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed in connection with U.S. Serial No. 09/826,589, filed April 5, 2001. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and

Applicant : Ann Marie Schmidt, et al.
Serial No.: 10/665,687
Filed : September 19, 2003
Page 11

Trademark Office, since they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier effective filing date under 35 U.S.C. §120. A copy of above-listed reference 17 is submitted herewith, as Exhibit 1.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.


I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

16/09

Alan J. Morrison
Reg. No. 37,399

Date

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. No. (212) 278-0400



Form PTO-1449
Commerce

Department of
Patent and Trademark Office

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.
575-55873-BA-PCT-
US/JPW/AJM/AAB

Serial No.
10/665,867

Applicant(s)
Ann Marie Schmidt, et al.

Filing Date
September 19, 2003

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate
	5	6	8	8	6	5	3	11/18/97	Ulrich, et al.			
	5	8	6	4	0	1	8	1/26/99	Morser, et al.			
	5	9	7	6	8	3	2	11/2/99	Hitomi, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number							Date	Country	Class	Subclass	Translation		
		WO	9	7	3	9	1	2	1	10/23/97	PCT			Yes	No
WO		9	7	3	9	1	2	5		10/23/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412;
	Borchelt, D. R., et al. (1996). Familial Alzheimer's Disease-linked presenilin 1 variants elevate A β 1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013;
	Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6):1699-1712;
	Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15(12):1835-1842;
	Cai, X-D., et al. (1993). Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259: 514-516;
	Citron, M., et al. (1997). Mutant presenilins of Alzheimer's Disease increase production of 42-residue amyloid β -protein in both transfected cells and transgenic mice. Nature Medicine 3(1): 67-72;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-144

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-BA-PCT-
US/JPW/AJM/AABSerial No.
10/665,867Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

INFORMATION DISCLOSURE CITATION
 (Use several sheets if necessary)
U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Dell'Angelica, E.C., et al. (1994). Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J. Biol. Chem. 269: 28929-28936;
	Fahey, T., et al. (1991). Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res. 50: 308-313;
	Fu, M-X., et al. (1996). The advanced glycation end product, N ^ε -(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986;
	Giardino, I., et al. (1994). Nonenzymatic glycosylation <i>in vitro</i> and in bovine endothelial cells alters basic fibroblast growth factor activity. J. Clin. Invest. 94: 110-117;
	Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for vascular diseases. Science 272: 689-693.;
	Hofmann, M. A., et al. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell 97:889-901;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





**Form PTO-144 U.S. Department of Commerce
Patent and Trademark Office**

Atty. Docket No.
575-55873-BA-PCT-
US/JPW/AJM/AAB

Serial No.
10/665,867

Applicant(s)
Ann Marie Schmidt, et al.

Filing Date
September 19, 2003

Group Art Unit

**INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	Li, J. and A.M. Schmidt (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. <i>J. Biol. Chem.</i> 272: 16498-16506;
	Lorenzo, A. and B.A. Yanker (1994). β -amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. <i>Proc. Nat. Acad. Sci. USA</i> 91: 12243-12247;
	Mattson, M. P. and Y. Goodman (1995). Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. <i>Brain Res.</i> 676: 219-224;
	Miyata, T., et al. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE- β 2 Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. <i>J. Clin. Invest.</i> 98: 1088-1094;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
and Trademark Office
INFORMATION DISCLOSURE CITATION
 (Use several sheets if necessary)
Atty. Docket No.
575-55873-BA-PCT-
US/JPW/AJM/AABSerial No.
10/665,867Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Translation	
							Yes	No


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Nakamura, Y., et al. (1993). Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143(6): 1649-1656;
	Nepper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267: 14998-15004;
	Palinski, W., et al. (1995). Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscl. Thromb. and Vasc. Biol. 15(5): 571-582;
	Park, L., et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4: 1025-1031;
	Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB		Serial No. 10/665,867			
		Applicant(s) Ann Marie Schmidt, et al.					
		Filing Date September 19, 2003		Group Art Unit			
		U.S. PATENT DOCUMENTS					
Examiner Initials	Document Number	Date	Name	Class	Subclass		
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Reddy, S., et al. (1995). N ^ε -(Carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878;						
	Renard, C., et al. (1997). Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharm. 52: 54-62;						
	Ritthaler, U., et al. (1995). Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease, Am. J. Pathol. 146: 688-694;						
	Roher, A. E., et al. (1996). Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's Disease. J. Biol. Chem. 271(34): 20631-20635;						
	Schleicher, E. D., et al. (1997). Increased accumulation of the glycoxidation product N ^ε -(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99: 457-468;						
EXAMINER			DATE CONSIDERED				



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB		Serial No. 10/665,867	
					Applicant(s) Ann Marie Schmidt, et al.			
					Filing Date September 19, 2003		Group Art Unit	
U.S. PATENT DOCUMENTS								
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
FOREIGN PATENT DOCUMENTS								
Examiner Initials		Document Number	Date	Name	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Schmidt, A. M., et al. (1995). Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. <i>J. Clin. Invest.</i> 96: 1395-1403;						
		Schmidt, A. M., et al. (1994). Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. <i>Proc. Nat'l Acad. Sci. USA</i> 91: 8807-8811;						
		Schmidt, A. M., et al. (1992). Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. <i>J. Biol. Chem.</i> 267: 14987-14997;						
		Schmidt, A. M., et al. (1994). Cellular receptors for advanced glycation end products. <i>Arterioscler. Thromb.</i> 14:1521-1528;						
		Schmidt, A. M., et al. (1995). The dark side of glucose. (News and Views). <i>Nature Medicine</i> 1: 1002-1004;						
EXAMINER			DATE CONSIDERED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								



Form PTO-1449

Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-BA-PCT-
US/JPW/AJM/AABSerial No.
10/665,867INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Translation
							Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Schmidt, A. M., et al. (1993). Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 92: 2155-2168;
	Schmidt, A. M., et al. (1997). The V-domain of receptor for advanced glycation endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetic complications. Circulation Supplement 96:#194, p. I-37;
	Schmidt, A. M., et al. (1994). The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J. Biol. Chem. 269: 9882-9888;
	Schmidt, A.M., et al. (1998). RAGE: a receptor with a taste for multiple ligands and varied pathophysiologic states. Hormones and Signaling 1:41-63;
	Sell, D., et al. (1989). Structure elucidation of a senescence cross-link from human extracellular matrix; implication of pentoses in the aging process. J. Biol. Chem. 264:21597-21602;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449		U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office				Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB		Serial No. 10/665,867	
						Applicant(s) Ann Marie Schmidt, et al.			
						Filing Date September 19, 2003		Group Art Unit	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									
U.S. PATENT DOCUMENTS									
Examiner Initials		Document Number		Date	Name	Class	Subclass	Filing Date If Appropriate	
FOREIGN PATENT DOCUMENTS									
Examiner Initials		Document Number		Date	Name	Class	Subclass	Translation	
								Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
		Soulis, T., et al. (1997). Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40: 619-628;							
		Turner, R.S., et al. (1997). Amyloids β_{40} and β_{42} are generated intracellularly in cultured human neurons and their secretion increases with maturation. J. Biol. Chem. 271(15): 8966-8970;							
		Vitek, M.P., et al. (1994). Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Nat'l Acad. Sci. USA 91: 4766-4770;							
		Vlassara, H., et al. (1995). Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Molec. Med. 1: 634-646;							
		Vlassara, H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70: 138-151;							
EXAMINER				DATE CONSIDERED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									





Form PTO-1449

Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
575-55873-BA-PCT-
US/JPW/AJM/AABSerial No.
10/665,867INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicant(s)
Ann Marie Schmidt, et al.Filing Date
September 19, 2003

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Yan, S. D., et al. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269: 9889-9897;
	Yan, S. D., et al. (1996). RAGE and amyloid- β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691;
	Yan, S. D., et al. (1997). Amyloid- β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Nat'l Acad. Sci. 94: 5296-5301;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.